Why a $2.2M Cure Is Cheaper Than the Disease: The Economics of Cure Pricing
Casgevy costs $2.2M per patient — and it's a bargain. The real controversy isn't the price. It's the business model that cures break.
Lavine Hemlani
Founder & CEO
There's a drug that costs $2.2 million per patient, and insurers pay it without blinking. It's called Casgevy — the first CRISPR-based cure approved for sickle cell disease. One treatment. Done. Everyone's instinct says the price is obscene. Run the numbers and the instinct breaks.
The math nobody does
A sickle cell patient costs the healthcare system millions over a lifetime: hospitalizations, transfusions, crisis care, decades of it. Against that, $2.2 million once is a discount. The sticker price feels outrageous only because we're used to paying for disease in installments rather than all at once.
The real controversy isn't the price — it's the business model
Here's what most people miss. Pharma was built on recurring revenue: a pill you take forever. A cure is a one-time sale that destroys its own market. Every patient you fix is a customer you lose.
That's why cures terrify investors more than they excite them. A chronic-treatment franchise is an annuity; a cure is a decaying asset the moment it succeeds. The financial logic of the industry was optimized for management, not resolution.
Who wins the next era
The companies that crack cure-pricing will own the next era of the industry. The models being built to solve it:
- Outcomes-based deals — the payer pays in full only if the cure holds.
- Installment / annuity models — the one-time cure is paid for over years, matching cost to realized benefit.
- Government buyouts — a public payer purchases access for a whole population at a negotiated price.
Each of these is an attempt to make a one-time cure financeable inside a system that was built to bill forever.
Why this matters for founders and investors
If you're building or backing a curative therapy, the science is only half the problem. The commercial model — how the cure gets paid for without collapsing its own revenue — is now a core part of the investment thesis and the diligence conversation. We spent a century learning to treat disease profitably. The harder problem was always how to afford ending it.
Frequently asked questions
Why does Casgevy cost $2.2 million?
Because it's a one-time CRISPR cure for sickle cell disease, priced against the multimillion-dollar lifetime cost of managing the disease — which it replaces.
Why are one-time cures hard for pharma to commercialize?
The traditional model relies on recurring revenue from ongoing treatment. A cure is a single sale that eliminates the future revenue from that patient, so it requires new pricing models to be financeable.
What pricing models make cures viable?
Outcomes-based contracts, installment/annuity payments, and government or population-level buyouts — all designed to spread or condition payment for a one-time therapy.
Zenith advises life sciences founders on the financial and commercial models behind their science — from cure-pricing strategy to transaction readiness. Book a Transaction Readiness Audit.
Need help with your financials?
Let's build your financial foundation together.